EUCTR2012-002252-17-DE进行中（未招募）不适用
Interventional, randomised, double-blind, parallel-group, placebo-controlled, active-reference, flexible-dose study of brexpiprazole in patients with acute schizophrenia - 14644A Protocol
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 465
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The patient has schizophrenia, diagnosed according to DSM-IV-TR™ and
- •confirmed by the Mini International Neuropsychiatric Interview (MINI).
- •The patient has an acute exacerbation of psychotic symptoms and marked
- •deterioration of usual function.
- •The patient is willing to be hospitalised from the Screening Visit through
- •The patient will benefit from hospitalisation or continued hospitalisation for
- •treatment of a current acute relapse of schizophrenia at study entry.
- •The patient has a history of relapse and/or exacerbation of symptoms when
- •not receiving antipsychotic treatment, excluding the current episode.
- •The patient agrees to protocol-defined use of effective contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 455
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •The patient has a current Axis I diagnosis (DSM-IV-TR™ criteria) other
- •than schizophrenia established as primary diagnosis.
- •The patient suffers from a current Axis II diagnosis (DSM-IV-TR™
- •The patient suffers from mental retardation, organic mental disorders, or
- •mental disorders due to a general medical condition (DSM-IV-TR™
- •The patient, in the opinion of the investigator or according to Columbia
- •Suicide Severity Rating Scale (C-SSRS), is at significant risk of suicide.
- •The patient has clinically significant tardive dyskinesia or severe akathisia
- •at enrolment.
- •The patient has a history of neuroleptic malignant syndrome.
- •The patient has any relevant medical history or current presence of systemic
- •The patient has, at the Screening Visit an abnormal ECG or other abnormal
- •ECG tests that are, in the investigator's opinion, clinically significant.
- •The patient has a history of cancer, other than basal cell or Stage 1
- •squamous cell carcinoma of the skin, that has not been in remission for >5
- •years prior to the first dose of brexpiprazole.
- •The patient is, in the investigator's opinion, unlikely to comply with the
- •protocol or is unsuitable for any reason
研究者
相似试验
进行中（未招募）
不适用
Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentMajor Depressive DisorderEUCTR2012-001361-32-BGH. Lundbeck A/S1,922
进行中（未招募）
不适用
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentMedDRA version: 16.0Level: LLTClassification code 10025461Term: Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behaviorSystem Organ Class: 100000004873MedDRA version: 14.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873MedDRA version: 16.0Level: LLTClassification code 10025469Term: Major depressive disorder, single episode, severe degree, without mention of psychotic behaviorSystem Organ Class: 100000004873MedDRA version: 16.0Level: LLTClassification code 10025462Term: Major depressive disorder, recurrent episode, unspecified degreeSystem Organ Class: 100000004873MedDRA version: 16.0Level: LLTClassification code 10025467Term: Major depressive disorder, single episode, moderate degreeSystem Organ Class: 100000004873MedDRA version: 16.0Level: LLTClassification code 10025458Term: Major depressive disorder, recurrent episode, moderate degreeSystem Organ Class: 100000004873MedDRA version: 16.0Level: LLTClassification code 10025470Term: Major depressive disorder, single episode, unspecified degreeSystem Organ Class: 100000004873Major Depressive DisorderEUCTR2012-001380-76-ITH. Lundbeck A/S1,950
进行中（未招募）
1 期
A study to evaluate the effect and safety of a product named vortioxetine (used in depression) when combining vortioxetine tablets with an injection of vortioxetine. Investigator and subjects will be blinded.MedDRA version: 19.0Level: PTClassification code 10057840Term: Major depressionSystem Organ Class: 10037175 - Psychiatric disordersMajor Depressive DisorderEUCTR2015-005081-30-SKH. Lundbeck A/S54
进行中（未招募）
不适用
Brexpiprazole as an additional treatment to paroxetine or sertraline in adult patients suffering from post-traumatic stress disorder (PTSD)Post-traumatic stress disorder (PTSD)MedDRA version: 16.1Level: PTClassification code 10036316Term: Post-traumatic stress disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2012-004982-41-ITH. Lundbeck A/S790
进行中（未招募）
1 期
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentMajor Depressive DisorderEUCTR2012-001380-76-BGH. Lundbeck A/S2,924